Robert A. Copeland, President of Research and CSO at Epizyme, Inc. (EPZM), sold 2,500 shares at $13.45 ($34K) on 2017-06-06, disclosed to the SEC on 2017-06-07.
Scheduled sale ($34k) by President of Research and CSO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| EPZM | SELL | 2016-08-03 | $83K | — | Filing → |
| EPZM | SELL | 2016-07-07 | $80K | — | Filing → |
| EPZM | SELL | 2016-01-04 | $130K | — | Filing → |